Call for Abstracts/Case Studies

The Program Planning Committee encourages you to submit an abstract for a podium or poster presentation at the 2023 PDA Annual Meeting. Case studies are particularly desired.

This year's event will address common challenges to provide solutions to everyone in the industry, from early career professionals to manufacturing leaders. We are seeking abstracts on a wide variety of topics, including, but not limited to:

- **Analytical method development and lifecycle management**
  (e.g., Improving method development and lifecycle management to speed the release of medicinal products for patient access)

- **Contamination control strategy**
  (e.g., Ensuring patient safety with enhanced control strategies to prevent contamination risks)

- **Facilities & Equipment**
  (e.g., Innovative manufacturing facilities that accelerate speed to the patient)

- **Human error reduction**
  (e.g., onboarding, training, coaching, and mentoring programs, utilizing human factors studies to ensure patient's safe administration of products)

- **Process intensification**

- **Risk Management**
  (e.g. Risk-based approach on equipment, facilities, products, modalities, and process focused on product quality and process improvement)

- **Supply chain**
  (e.g., disruptions, innovations, and advancements, supply shortages and partnerships for raw materials, finished products, etc., securing supply lanes and resources to prevent drug shortages, enhancing serialization and control of distribution to prevent counterfeits in the supply chain)

- **Technology**
  (e.g., roadmap, digitalization journey, digital strategy, implementation, and transformation, utilizing technology or personal hand-held devices that ensure patient compliance to the drug regimen, new drug delivery mechanisms that focus on end-user comfort)

- **Trends**
  (e.g., collaboration, evolution, pipeline development, shortening the timeline/speed from clinic to market, at-home diagnostics, preventing counterfeits in the market, personalized medicine, new technologies, emerging biotech, sustainability in the biopharmaceutical industry)

- **Regulatory**
  (e.g., adapting to evolving regulatory expectations, learnings from EUAs, expedited pathways, virtual auditing, submission strategies to ensure patients receive products quickly and safely)

Each abstract must include the following information to be considered:

- Abstract Title (Max 25 words)
- Abstract Overview (Max 200 words)
- Learning Objectives (Max 100 words)